- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04216290
En studie av kjemoterapi og stråleterapi sammenlignet med kjemoterapi og strålebehandling Plus MEDI4736 (Durvalumab) immunterapi for blærekreft som har spredt seg til lymfeknutene (INSPIRE-studien)
Fase II-studie av blærebesparende kjemoradiasjon med Durvalumab i klinisk stadium III, nodepositiv blærekreft (INSPIRE)
This phase II trial studies the benefit of adding an immunotherapy drug called MEDI4736 (durvalumab) to standard chemotherapy and radiation therapy in treating bladder cancer which has spread to the lymph nodes. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with durvalumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy and radiation therapy with the addition of durvalumab may work better in helping tumors respond to treatment compared to chemotherapy and radiation therapy alone. Patients with limited regional lymph node involvement may benefit from attempt at bladder preservation, and use of immunotherapy and systemic chemotherapy.
Studieoversikt
Status
Intervensjon / Behandling
- Legemiddel: Cisplatin
- Legemiddel: Fluorouracil
- Fremgangsmåte: Computed Tomography
- Fremgangsmåte: Magnetic Resonance Imaging
- Legemiddel: Gemcitabine Hydrochloride
- Stråling: Radiation Therapy
- Annen: Patient Observation
- Legemiddel: Mitomycin
- Biologisk: Durvalumab
- Fremgangsmåte: Cystoscopy
- Fremgangsmåte: Biopsy of Bladder
- Fremgangsmåte: Biospecimen Collection
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To compare the clinical complete response rate (cCR) after chemoradiotherapy (chemoRT) with or without durvalumab in node-positive bladder cancer patients.
SECONDARY OBJECTIVES:
I. To compare the toxicity profile in both arms using the Common Terminology Criteria for Adverse Events (CTCAE).
II. To estimate the progression-free survival (PFS) in both arms. III. To estimate overall survival (OS) post randomization in both arms. IV. To estimate the bladder intact event free survival (BIEFS) in both arms. V. To estimate the metastasis free survival (MFS) in both arms. VI. To estimate bladder cancer specific survival in both arms. VII. To estimate the complete clinical response duration in both arms. VIII. To estimate salvage cystectomy rates in both arms.
EXPLORATORY OBJECTIVE:
I. Planned subgroup analyses for clinical outcome (clinical complete response [CR] rate post chemoRT +/- durvalumab, MFS, OS, PFS) based on stratification factors.
TRANSLATIONAL OBJECTIVE:
I. To collect and bank tumor tissue and blood specimens at pre-and post-treatment with chemoRT +/- durvalumab to determine predictive or prognostic markers.
OUTLINE:
STEP 1 - Randomization: Patients are randomized to 1 of 2 arms.
ARM C: Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice a week (BIW) for 6 weeks; or cisplatin IV over 30-60 minutes once a week (QW) for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
ARM D: Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
STEP 2 - Registration: Patients are assigned to 1 of 2 arms.
ARM E: Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
ARM F: Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
After completion of study treatment, patients are followed up every 12 weeks for 1 year, every 6 months for year 2, and then annually for years 3-4.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Forente stater, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Forente stater, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Forente stater, 99508
- Providence Alaska Medical Center
-
-
Arkansas
-
Fort Smith, Arkansas, Forente stater, 72903
- Mercy Hospital Fort Smith
-
Hot Springs, Arkansas, Forente stater, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Burbank, California, Forente stater, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Palo Alto, California, Forente stater, 94304
- VA Palo Alto Health Care System
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forente stater, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Denver, Colorado, Forente stater, 80210
- AdventHealth Porter
-
Lakewood, Colorado, Forente stater, 80228
- Saint Anthony Hospital
-
Littleton, Colorado, Forente stater, 80122
- AdventHealth Littleton
-
Longmont, Colorado, Forente stater, 80501
- Longmont United Hospital
-
Parker, Colorado, Forente stater, 80138
- AdventHealth Parker
-
Pueblo, Colorado, Forente stater, 81004
- Saint Mary Corwin Medical Center
-
-
Delaware
-
Millville, Delaware, Forente stater, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Forente stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forente stater, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Forente stater, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Forente stater, 33308
- Holy Cross Hospital
-
Miami Beach, Florida, Forente stater, 33140
- Mount Sinai Medical Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forente stater, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forente stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forente stater, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Idaho Urologic Institute-Meridian
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forente stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Forente stater, 60504
- Rush-Copley Medical Center
-
Bloomington, Illinois, Forente stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forente stater, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Forente stater, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Forente stater, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Forente stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forente stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Danville, Illinois, Forente stater, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Forente stater, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forente stater, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Forente stater, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Forente stater, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Forente stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Hines, Illinois, Forente stater, 60141
- Edward Hines Jr VA Hospital
-
Kewanee, Illinois, Forente stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Lake Forest, Illinois, Forente stater, 60045
- Northwestern Medicine Lake Forest Hospital
-
Macomb, Illinois, Forente stater, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, Forente stater, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Forente stater, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Forente stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Forente stater, 61554
- Illinois CancerCare-Pekin
-
Pekin, Illinois, Forente stater, 61554
- OSF Saint Francis Radiation Oncology at Pekin
-
Peoria, Illinois, Forente stater, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forente stater, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Forente stater, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Peru, Illinois, Forente stater, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Forente stater, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Forente stater, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forente stater, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Urbana, Illinois, Forente stater, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, Forente stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Forente stater, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Forente stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forente stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Forente stater, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Forente stater, 40509
- Saint Joseph Hospital East
-
Louisville, Kentucky, Forente stater, 40202
- Jewish Hospital
-
Louisville, Kentucky, Forente stater, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Forente stater, 40207
- Baptist Health Louisville
-
-
Louisiana
-
Metairie, Louisiana, Forente stater, 70006
- East Jefferson General Hospital
-
Metairie, Louisiana, Forente stater, 70006
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
New Orleans, Louisiana, Forente stater, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, Forente stater, 70112
- Louisiana State University Health Science Center
-
-
Maine
-
Bangor, Maine, Forente stater, 04401
- Eastern Maine Medical Center
-
Brewer, Maine, Forente stater, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forente stater, 48118
- Chelsea Hospital
-
Detroit, Michigan, Forente stater, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Forente stater, 48503
- Hurley Medical Center
-
Flint, Michigan, Forente stater, 48503
- Genesys Hurley Cancer Institute
-
Lansing, Michigan, Forente stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Forente stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw, Michigan, Forente stater, 48601
- MyMichigan Medical Center Saginaw
-
Warren, Michigan, Forente stater, 48093
- Henry Ford Health Warren Hospital
-
Ypsilanti, Michigan, Forente stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Brainerd, Minnesota, Forente stater, 56401
- Essentia Health Saint Joseph's Medical Center
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy Hospital
-
Deer River, Minnesota, Forente stater, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Forente stater, 55805
- Essentia Health Cancer Center
-
Duluth, Minnesota, Forente stater, 55805
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Forente stater, 55805
- Miller-Dwan Hospital
-
Fridley, Minnesota, Forente stater, 55432
- Unity Hospital
-
Hibbing, Minnesota, Forente stater, 55746
- Essentia Health Hibbing Clinic
-
Sandstone, Minnesota, Forente stater, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Forente stater, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Ballwin, Missouri, Forente stater, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Cape Girardeau, Missouri, Forente stater, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Forente stater, 63703
- Mercy Cancer Center - Cape Girardeau
-
City of Saint Peters, Missouri, Forente stater, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Forente stater, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Forente stater, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, Forente stater, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Forente stater, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Forente stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forente stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Forente stater, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Forente stater, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Forente stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forente stater, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Forente stater, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forente stater, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Forente stater, 63080
- Missouri Baptist Sullivan Hospital
-
Sunset Hills, Missouri, Forente stater, 63127
- BJC Outpatient Center at Sunset Hills
-
-
Montana
-
Billings, Montana, Forente stater, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forente stater, 59405
- Great Falls Clinic
-
Great Falls, Montana, Forente stater, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Forente stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forente stater, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Forente stater, 68847
- CHI Health Good Samaritan
-
Omaha, Nebraska, Forente stater, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Forente stater, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Forente stater, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Forente stater, 68131
- Creighton University Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- University of New Mexico Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Forente stater, 45242
- Bethesda North Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Forente stater, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Bend, Oregon, Forente stater, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Forente stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forente stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Forente stater, 97420
- Bay Area Hospital
-
Newberg, Oregon, Forente stater, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Chadds Ford, Pennsylvania, Forente stater, 19317
- Christiana Care Health System-Concord Health Center
-
East Stroudsburg, Pennsylvania, Forente stater, 18301
- Pocono Medical Center
-
Hershey, Pennsylvania, Forente stater, 17033-0850
- Penn State Milton S Hershey Medical Center
-
-
South Carolina
-
Gaffney, South Carolina, Forente stater, 29341
- Gibbs Cancer Center-Gaffney
-
Greer, South Carolina, Forente stater, 29651
- Gibbs Cancer Center-Pelham
-
Spartanburg, South Carolina, Forente stater, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Forente stater, 29379
- SMC Center for Hematology Oncology Union
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37920
- University of Tennessee - Knoxville
-
-
Texas
-
Bryan, Texas, Forente stater, 77802
- Saint Joseph Regional Cancer Center
-
-
Virginia
-
Martinsville, Virginia, Forente stater, 24112
- Sovah Health Martinsville
-
-
Washington
-
Aberdeen, Washington, Forente stater, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Forente stater, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Forente stater, 98166
- Highline Medical Center-Main Campus
-
Centralia, Washington, Forente stater, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Forente stater, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Forente stater, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Forente stater, 98029
- Swedish Cancer Institute-Issaquah
-
Lacey, Washington, Forente stater, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Forente stater, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Forente stater, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Forente stater, 98122
- Swedish Medical Center-First Hill
-
Sedro-Woolley, Washington, Forente stater, 98284
- PeaceHealth United General Medical Center
-
Silverdale, Washington, Forente stater, 98383
- Saint Michael Cancer Center
-
Vancouver, Washington, Forente stater, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Forente stater, 99362
- Providence Saint Mary Regional Cancer Center
-
-
Wisconsin
-
Ashland, Wisconsin, Forente stater, 54806
- Duluth Clinic Ashland
-
Ashland, Wisconsin, Forente stater, 54806
- Northwest Wisconsin Cancer Center
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
-
Wyoming
-
Sheridan, Wyoming, Forente stater, 82801
- Welch Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
• STEP 1 (RANDOMIZATION) ELIGIBILITY CRITERIA:
-
Patient must be >= 18 years of age.
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at the time of step 1 randomization.
-
Patient must have histologically proven pure or mixed urothelial cancer of the bladder.
- NOTE: Small cell carcinoma is excluded, however other variant histologies are permitted provided a component of urothelial carcinoma is present.
-
Patient must have documented node-positive and non-metastatic disease (any T, any N, M0).
Node positivity must have been defined prior to receiving any systemic chemotherapy or induction chemotherapy. Node positivity can fall into either of the following categories and will be defined by imaging and/or biopsy:
-
A lymph node >= 1.0 cm in short axis on imaging (i.e., CT or MRI or positron emission tomography [PET]/CT).
-
A lymph node that is < 1 cm on imaging with either a biopsy confirming involvement with cancer or high suspicion of cancer.
• For patients who have received induction chemotherapy (any type of systemic chemotherapy) for node positive bladder cancer prior to enrollment, there must be no signs of disease progression (CR/partial response [PR] or stable disease [SD]) based on restaging imaging and cystoscopy, which consists of:
-
CT chest, abdomen, and pelvis obtained after completion of induction chemotherapy and within 8 weeks prior to step 1 randomization.
** NOTE: MRI can be used instead of CT per treating physician discretion.
-
Cystoscopic evaluation and attempt to perform maximal transurethral resection of bladder tumor (TURBT) performed by the participating urologist after completion of induction chemotherapy and within 12 weeks prior to step 1 randomization. If maximal TURBT is not possible for medical reasons, the enrollment must be discussed and approved with the study chair. Documentation of correspondences with the study chair must be kept on file.
-
Patients who achieve CR upon cystoscopy per urologist with no visible tumor (i.e., no need for additional TURBT), are allowed to proceed in the study as adequate resection with no residual disease in bladder.
• For patients who have did not receive induction chemotherapy (any type of systemic chemotherapy) for node positive bladder cancer prior to enrollment, the following must be obtained:
-
CT chest, abdomen, and pelvis completed within 8 weeks prior to step 1 randomization.
** NOTE: MRI can be used instead of CT per treating physician discretion.
-
Cystoscopic evaluation and attempt to perform maximal TURBT performed by the participating
urologist within 12 weeks prior to step 1 randomization. If maximal TURBT is not possible for medical reasons, the enrollment must be discussed and approved with the study chair.
Documentation of correspondences with the study chair must be kept on file.
-
For patients who may need repeat TURBT if their old TURBT has fallen out of window: If urologist determine no visible tumor (i.e., no need for additional resection) upon cystoscopy, they are allowed to proceed in the study as complete resection. • Patient must not have received any previous radiation therapy to the pelvic area.
- Patient must agree to undergo CT simulation and treatment planning. If this is the first case registered at the site, then a pre-treatment radiation therapy (RT) review will be required and will take up to 3 business days. The patient cannot start radiation treatment prior to successful completion of this pre-treatment review. Therefore, careful planning is necessary to meet the deadline of starting radiation within 20 business days of step 1 randomization.
- Patient must not have presence of concomitant active upper tract tumors or urethra tumors.
History of previously adequately treated non-muscle invasive bladder cancer (NMIBC) are eligible. Previously treated urothelial cancer or histological variant at any site outside of the urinary bladder are allowed, provided they have been Ta/T1/carcinoma in situ (CIS) and post treatment follow up imaging and endoscopic evaluation shows no evidence of disease.
- Patients with previous exposure to immune checkpoint inhibitor for non-muscle invasive disease are eligible. If given for NMIBC, the last dose must have been completed > 12 months prior to step 1 randomization.
- Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
All patients of childbearing potential must have a blood test or urine study within 14 days prior to step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
- Patients must not expect to conceive or father children by using accepted and effected method(s) of contraception or by abstaining from sexual intercourse from the time of step 1 randomization for the duration of their participation in the study and continue for at least 3 months after the last dose of protocol treatment.
- Leukocytes >= 3,000/mcL (obtained < 14 days prior to step 1 randomization).
- Absolute neutrophil count (ANC) >= 1,500/mcL (obtained < 14 days prior to step 1 randomization).
- Hemoglobin >= 9 g/dL (obtained < 14 days prior to step 1 randomization).
- Platelets >= 100,000/mcL (obtained < 14 days prior to step 1 randomization).
- Total bilirubin <= 1.5 x institutional upper limit of normal (ULN) (obtained < 14 days prior to step 1 randomization).
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) <= 2.5 x institutional ULN (obtained < 14 days prior to step 1 randomization).
- Adequate renal function as evidenced by calculated (Cockcroft's formula) creatinine clearance or 24 hours actual creatinine clearance >= 30mL/min. The creatinine used to calculate the clearance result must have been obtained within 14 days prior to step 1 randomization. Actual body weight, not ideal body weight, must be used in the calculation.
- Patients with human immunodeficiency virus (HIV) on effective anti-retroviral therapy with undetectable viral load within 6 months of step 1 randomization are eligible for this trial.
- For patients with autoimmune conditions, patient must not have history of prior documented autoimmune disease within 2 years prior to step 1 randomization. * NOTE: Patient with vitiligo, Grave's disease, eczema or psoriasis (not requiring systemic treatment within 2 years prior to step 1 randomization) are not excluded. Patients with history of completely resolved childhood asthma or atopy are not excluded. Patients with asthma not
requiring more than 10 mg/d or equivalent of prednisone are not excluded. Patients with well- controlled hypothyroidism on thyroxine replacement will be eligible as well. Patients with known history of hypoadrenalism on maintenance steroids will be eligible. Patients with type I diabetes mellitus will be eligible, provided their disease is well controlled. History of autoimmune related alopecia is also not an exclusion criteria.
-
Patient with active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) are not eligible.
-
Patient with a history of and/or confirmed pneumonitis are not eligible.
-
Patient with a history of primary immunodeficiency are not eligible.
-
Patient with history of allogeneic organ transplant are not eligible. • Patient must not have an active infection, including:
-
Tuberculosis (based on clinical evaluation that includes clinical history, physical examination, and radiographic findings, and tuberculosis testing in line with local practice).
-
Hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result). Past or resolved HBV infection (defined as the presence of hepatitis b core antibody [anti-HBc] and absence of HBsAg) are eligible.
-
Hepatitis C. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction test is negative for HCV ribonucleic acid (RNA).
• Patient must not have clinically significant liver disease that precludes patient from treatment regimens prescribed on the study (including, but not limited to, active viral, alcoholic or other autoimmune hepatitis, cirrhosis or inherited liver disease).
• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Site is encouraged to discuss with the study chair if needed prior to enrollment.
• Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class IIB or better.
• Patient must not have received live attenuated vaccine within 30 days prior to the first dose of durvalumab
-
NOTE: Patient, if enrolled, must not receive live vaccine whilst receiving durvalumab and up to 30 days after the last dose of durvalumab.
-
NOTE: Patient is permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist (registered trademark) are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily in order to minimize an overlap of adverse events).
• Patient must not have current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
-
Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).
-
Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
-
Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
• Patient must not have any unresolved toxicity (National Cancer Institute [NCI] CTCAE grade >=2) from previous anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values.
-
NOTE: Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study chair.
-
NOTE: Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study chair.
Documentation of correspondences with the study chair must be kept on file.
• STEP 2 (REGISTRACTION: ADJUVANT DURVALUMAB VERSUS [VS] OBSERVATION)
ELIGIBILITY CRITERIA:
-
Patient must have evaluation to determine clinical outcome post step 1 treatment (chemoRT+/-durvalumab) with imaging (CT chest, abdomen, and pelvis) (preferably contrast with urogram, if not contraindicated) and cystoscopy with biopsy confirmation to ensure no progression and absence of >= T2 disease in the bladder. Patient should be registered to step 2 within 28 days from the determination of primary response to step 1 treatment. However, for patients previously on Arm C, an additional 4 week delay to step 2 registration is allowed.
-
Patient on the chemoRT+ durvalumab (Arm C) must meet the following:
-
Patient must have achieved either complete clinical response OR have demonstrated clinical benefit prior to continuing onto adjuvant durvalumab.
-
Patients who are to go on the adjuvant durvalumab (Arm E) must have recovered to at least grade 2 or less immune related adverse event (AE) prior to starting treatment except for immune related alopecia, clinically asymptomatic endocrinopathies. For patients who may have gotten immune related AEs during chemoRT+ durvalumab (Arm C), step 2 registration could be delayed up to additional 4 weeks to ensure recovery to at least grade 2 or lower prior to starting adjuvant therapy. However patients with durvalumab related AEs that require permanent discontinuation of durvalumab will not continue on the adjuvant treatment regardless of the response.
-
Patient must not have experienced immune related neurological disorder described as Guillain- Barré syndrome, myasthenic syndrome or myasthenia gravis, or meningoencephalitis during chemoRT+ durvalumab treatment.
-
Patient must not have experienced immune related myocarditis or immune related pericarditis during chemoRT+ durvalumab treatment.
-
ANC >= 1,000 mcL (must be obtained < 28 days prior to step 2 registration).
-
Hemoglobin >= 8g/dL (must be obtained < 28 days prior to step 2 registration).
-
Platelets >= 70,000 mcL (must be obtained < 28 days prior to step 2 registration).
- NOTE: If recovery is not achieved, blood counts could be repeated weekly and step 2 registration could be delayed up to additional 4 weeks.
-
-
Patient on the chemoRT arm (Arm D) must have achieved either complete clinical response OR have demonstrated clinical benefit prior to be placed on the observation alone arm (Arm F).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Step 1, Arm C (durvalumab, radiation therapy, chemotherapy)
Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study. |
Given IV
Andre navn:
Given IV
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Given IV
Andre navn:
Undergo radiation therapy
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo cystoscopy
Andre navn:
Undergo bladder biopsy
Andre navn:
Undergo tumor tissue and blood sample collection
Andre navn:
|
|
Aktiv komparator: Step 1, Arm D (radiation therapy, chemotherapy)
Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study. |
Given IV
Andre navn:
Given IV
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Given IV
Andre navn:
Undergo radiation therapy
Andre navn:
Given IV
Andre navn:
Undergo cystoscopy
Andre navn:
Undergo bladder biopsy
Andre navn:
Undergo tumor tissue and blood sample collection
Andre navn:
|
|
Eksperimentell: Step 2, Arm E (durvalumab)
Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Given IV
Andre navn:
Undergo cystoscopy
Andre navn:
Undergo bladder biopsy
Andre navn:
Undergo tumor tissue and blood sample collection
Andre navn:
|
|
Aktiv komparator: Step 2, Arm F (observation)
Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo observation
Andre navn:
Undergo cystoscopy
Andre navn:
Undergo bladder biopsy
Andre navn:
Undergo tumor tissue and blood sample collection
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Complete Response
Tidsramme: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
Clinical complete response is defined as complete response in bladder and nodes with no distant metastases. |
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment-related Grade 3 or Higher Adverse Event Rate
Tidsramme: Assessed every 3 weeks while on treatment, up to 4 years
|
Proportion of patients with grade 3 or higher adverse events that are definitely, probably or possibly related to protocol therapies per the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. |
Assessed every 3 weeks while on treatment, up to 4 years
|
|
Progression-free Survival (PFS)
Tidsramme: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
Progression-free survival is defined as the time from randomization to disease progression or death, whichever occurs first. Patients with evidence of progression in the bladder or lymph nodes that are unresectable, or with a presence of distant metastasis are considered as experiencing disease progression. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For response evaluation by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. |
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
|
Duration of Complete Response
Tidsramme: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
Duration of complete response is defined as the time from documentation of complete response to disease progression, death or last disease assessment. Clinical complete response is defined as complete response in bladder and nodes with no distant metastases. For progression in bladder: cystoscopy will be performed and documentation of T2 disease is needed either by pathology or by treating urologist (this is to incorporate circumstances such - when T2 is suspected by urologist but adequate TURBT could not be done for concerns of perforating the bladder). Pathological confirmation is preferred. For progression evaluated by imaging: at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. |
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
|
1-year Overall Survival (OS) Rate
Tidsramme: Assessed at baseline, every 12 weeks for 1 year
|
Overall survival is defined as the time from randomization to death or date last known alive. The method of Kaplan-Meier was used to estimate 1-year OS rate. |
Assessed at baseline, every 12 weeks for 1 year
|
|
Bladder Intact Event Free Survival (BIEFS)
Tidsramme: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
BIEFS is defined as time from randomization to presence of muscle invasive bladder cancer, clinical evidence of progression of nodal involvement or development of met disease, radical cystectomy, or death due to any cause. |
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
|
Metastasis-free Survival (MFS)
Tidsramme: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
MFS is defined as time from randomization to first evidence of metastatic disease or death from any cause. |
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
|
1-year Bladder Cancer-specific Survival Rate
Tidsramme: Assessed at baseline, every 12 weeks for 1 year
|
Bladder cancer-specific survival is the time from randomization to death from bladder cancer. Deaths due to other causes will be considered competing events and patients known to be alive will be censored at the date of last contact. The method of Kaplan-Meier was used to estimate 1-year bladder cancer-specific survival rate. |
Assessed at baseline, every 12 weeks for 1 year
|
|
Salvage Cystectomy Rate
Tidsramme: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
Proportion of patients with salvage cystectomy performed |
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Associations Between Clinical Outcomes and Stratification Factors
Tidsramme: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
Planned subgroup analyses for clinical outcome (Clinical CR rate post chemoRT+/- durvalumab, MFS, OS, PFS) based on stratification factors. |
Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4
|
|
To Collect and Bank Tumor Tissue and Blood Specimens at Pre- and Post-treatment With chemoRT +/- Durvalumab to Determine Predictive or Prognostic Markers.
Tidsramme: Assessed at baseline and 16 weeks
|
To collect and bank tumor tissue and blood specimens at pre- and post-treatment with chemoRT +/- durvalumab to determine predictive or prognostic markers. |
Assessed at baseline and 16 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Monika Joshi, ECOG-ACRIN Cancer Research Group
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Urologiske neoplasmer
- Urinblæresykdommer
- Neoplasmer i urinblæren
- Health Services Administration
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Undersøkelsesteknikker
- Metoder
- Terapeutikk
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Minimalt invasive kirurgiske inngrep
- Kvalitet på helsehjelpen
- Fysiske fenomener
- Indoler
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Deoxycytidine
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Elementer
- Metaller
- Diagnostiske teknikker, kirurgisk
- Endoskopi
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Uracil
- Pyrimidinoner
- Metaller, tunge
- Immunoglobulinisotyper
- Sulfider
- Anioner
- Ioner
- Elektrolytter
- Hydrogensulfid
- Platinumforbindelser
- Resultatvurdering, helsehjelp
- Resultat og prosessvurdering, helsehjelp
- Kinoner
- Overgangselementer
- Aziriner
- Urologiske kirurgiske inngrep
- Urogenitale kirurgiske inngrep
- Diagnostiske teknikker, urologisk
- Mitomycins
- Indolekinoner
- Gemcitabin
- Fluorouracil
- Immunoglobulin G
- Cisplatin
- Mitomycin
- 1,2-diaminocykloheksanplatina II sitrat
- Strålebehandling
- Observasjon
- Stråling
- Prøvehåndtering
- Magnetisk resonansspektroskopi
- Durvalumab
- Disulfider
- Vakelig venting
- Platinum
- Dehydroftorafur
- Cystoskopi
- MitozyTrex
Andre studie-ID-numre
- NCI-2019-08628
- U10CA180820 (U.S. NIH-stipend/kontrakt)
- NCI-2019-08628 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- EA8185 (Annen identifikator: CTEP)
- EA8185 (Annen identifikator: ECOG-ACRIN Cancer Research Group)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .